(Washington Composite Electric) The United States approved Paxlovid's emergency use authorization on Wednesday, the United States on Wednesday. This is the first crown disease treatment drug that can be taken at home in the United States.tool.
The US Food and Pharmaceutical Administration (FDA) approves PAXLOVID for the treatment of children over 12 years old and adult patients who have mild diseases, including high -risk patients who may develop into severe illnesses.
After various scientific assessments, the bureau believes that this drug may be effective in treating patients with mild disease, and known and potential benefits than known and potential risks.
The effective rate of death of high -risk people in hospitalization is nearly 90%
Paxlovid consisting of two antiviral drugs, including a new drug and the long -used Litonaviwell(Ritonavir).According to the clinical trial conducted by Pfizer, Paxlovid's effective rate in preventing high -risk patients in preventing high -risk patients is nearly 90%.Laboratory data also shows that it can effectively fight Omikon's variants.
This drug can only be obtained through prescriptions. Patients should take it as soon as possible after the diagnosis, and start taking it within five days after the symptoms occur, every 12 hours, lasting for five days.
Merck oral medication Monililavo can treat high -risk adult patients
Following the use of Pfizer's pills, the FDA also approved Merck on ThursdayCrown disease oral medicine Molnupiravir is used to treat high -risk adult patients.
FDA scientist Kavzuni said the authorization provided additional treatment options for the confrontation of coronary virus.
FDA emphasized that Paxlovid and Monobi Lavi should be auxiliary means and cannot replace the vaccine. The vaccine is still the front line tool against crown disease.
Johnshop Hopkins Senior Scholar Ada, a senior scholar, described that Paxlovid's approval is an important milestone, marking the crown disease to become a easier and more controllable infected disease and move further.
Infectious Disease Expert of the University of Fandeburg Medical College, Shafner said that Pfizer's oral medicine is expected to fill the treatment gap caused by Omikon.At present, of the three monoclonal antibody drugs used by the United States to treat crown diseases, the two most widely used effects on Omikon are significantly low. Although the other is effective, the supply is limited.
But Adelia pointed out that there are still two key issues."This drug will be scarce in the next few weeks. It also requires patients to get timely diagnosis to maximize effectiveness, but this may be difficult when the testing work continues to face problems."
The U.S. government has ordered 10 million PAXLOVID courses. The price of each course of treatment is about $ 530 (about S $ 720), of which 265,000 for treatment is expected to be delivered in January next year.Pfizer has prepared to start delivery immediately, and increases the expected production of next year from 80 million treatment to 120 million.
U.S. President Biden described that Paxlovid was approved by good news. As Omikon raged, this would greatly reduce the cases of hospitalization and death.He promised to provide Pfizer with the resources required to accelerate the production of this drug, including citing national defense production laws when necessary.
Cancel the purchase of Phaxlovid
(Paris Composite Electric) (Paris Composite Electric) The Test data of the Oral Drug Oral Medicine Monibirovir, a US Pharmaceutical Factory in ParisPurchase this drug.France has ordered Paxlovid, the crown disease oral medication of Pfizer in another American company, hoping to receive the goods before the end of January next year.
French Minister of Health Wei Lang said on March that due to the poor results of Molnupiravir's latest test results, France has canceled the purchase of 50,000 doses.He said France would not suffer any losses.
France is the first country to publicize the cancellation of Monimi Libavir.The test data released last month showed that this drug could reduce the risk of hospitalization and death of coronary disease by about 30%, lower than about 50%of the previous trials.
Merck spokesman confirmed that the French health department refused to approve the use of Monabelae earlier this month.
The company is continuing to cooperate with the approval of the European Pharmaceutical Administration. The bureau is expected to finalize whether to approve the use of Monabelavi and Paxlovid next year.
Wei Lang revealed that France has purchased some Paxlovid pills and is expected to arrive next month.The test results showed that the effective rate of this drug in preventing high -risk patients' hospitalization and death has reached nearly 90%.
So far, Merck has signed an agreement to supply Monillai Laive with more than 30 countries, and 12 of them have received goods.
